ibrutinib,venetoclax,Obinutuzumab
roche,janssen,abbvie,biogen
['lymsm', 'cll']
congress | #eha2022 | lba: barbara eichhorst, presents results from gaia/cll13 trial on co-primary endpoint of pfs which was met. superior pfs at 3 y for both gv-based tx.
- giv vs cit: 90.5% vs 75.5%
- gv vs cit: 87.7% vs 75.5%
- rv vs cit: not superior #cll #lymsm 
A global education platform providing clinical updates on a range of lymphoma subtypes and chronic lymphocytic leukemia (#CLL) #lymsm